Niranjan Rao

1.1k citations

26 papers · 861 indexed · h-index 11

Impact in

Dermatology top 2%
- Dermatology and Skin Diseases
Immunology and Allergy top 5%
- Allergic Rhinitis and Sensitization

Papers in

Immunology and Allergy 3
- Allergic Rhinitis and Sensitization 3
Genetics 5
- Chronic Lymphocytic Leukemia Research 3

Co-authors: H. Mengel Birgitte Søgaard Frank Larsen Daniel Ventura Wattanaporn Abramowitz David J. Zammit Gail J. Roboz Mark J. Levis
Journals: Journal of Clinical Oncology (5 papers)Molecular Cancer Therapeutics (4 papers)Blood (4 papers)Cancer Research (3 papers)Journal of the American Academy of Dermatology (1 paper)
Partner nations: United States India Canada

In The Last Decade

Niranjan Rao

26 papers receiving 833 citations

Peers

Countries citing papers authored by Niranjan Rao

Since Specialization

Citations

This map shows the geographic impact of Niranjan Rao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Niranjan Rao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Niranjan Rao more than expected).

Fields of papers citing papers by Niranjan Rao

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Niranjan Rao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Niranjan Rao. The network helps show where Niranjan Rao may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Niranjan Rao, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Niranjan Rao Line = papers co-authored together Niranjan Rao links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Oral spleen tyrosine kinase/Janus Kinase inhibitor gusacitinib for the treatment of chronic hand eczema: Results of a randomized phase 2 study Journal of the American Academy of Dermatology ·Pablo A. Jimenez, Howard Sofen, Robert Bissonnette, Mark Lee, Joseph F. Fowler, David J. Zammit, Yusong Chen, Niranjan Rao, Louis Denis, Sandeep Kumar Gupta	2023	25
2	A clinical study to effect of Dhanyamla Parisheka in Rheumatoid Arthritis Journal of Ayurveda and Integrated Medical Sciences ·Kathy Mullin, Niranjan Rao, Nobuyuki Inaizumi	2022	1
3	ASN004, A 5T4-targeting scFv-Fc Antibody–Drug Conjugate with High Drug-to-Antibody Ratio, Induces Complete and Durable Tumor Regressions in Preclinical Models Molecular Cancer Therapeutics ·Roger A. Smith, David J. Zammit, Nitin K. Damle, Helen Usansky, Sanjeeva Reddy, Jun-Hsiang Lin, Mahesh Mistry, Niranjan Rao, Louis Denis, H Afzal	2021	19
4	The oral Janus kinase/spleen tyrosine kinase inhibitorASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate‐to‐severe atopic dermatitis: results from a randomized double‐blind placebo‐controlled study British Journal of Dermatology ·Robert Bissonnette, Catherine Maari, Seth Forman, Neal Bhatia, Ahmed Aldandan, Joseph F. Fowler, Stephen K. Tyring, David M. Pariser, Howard Sofen, Sunil Dhawan, A.L. Shloss, David J. Zammit, Helen Usansky, L. Denis, Niranjan Rao, Teresa Song, Ana B. Pavel, Emma Guttman‐Yassky	2019	101
5	Oral Janus kinase/SYK inhibition (ASN002) suppresses inflammation and improves epidermal barrier markers in patients with atopic dermatitis Journal of Allergy and Clinical Immunology ·Ana B. Pavel, Teresa Song, Hyun Je Kim, Ester Del Duca, James G. Krueger, Celina Dubin, Xiangyu Peng, Hui Xu, Ning Zhang, Yeriel Estrada, Louis Denis, Niranjan Rao, H Afzal, David J. Zammit, Robert Bissonnette, Emma Guttman‐Yassky	2019	110
6	559 ASN002 a dual oral inhibitor of JAK/SYK signaling improves clinical outcomes and associated cutaneous inflammation in moderate-to-severe atopic dermatitis patients Journal of Investigative Dermatology ·Emma Guttman‐Yassky, Ana B. Pavel, Teresa Song, Paula Louíse de Lima Felipe Ewald, David J. Zammit, Ruihong Xiao, Niranjan Rao	2018	10
7	Abstract B150: ASN007, a novel oral ERK inhibitor, shows robust antitumor activity in RAS mutant cancer models Molecular Cancer Therapeutics ·Sanjeeva Reddy, Sivanandhan Dhanalakshmi, Marta Carlini, Niranjan Rao, Roger A. Smith, Scott K. Thompson	2018	2
8	Abstract 4204: ASN002: A novel dual SYK/JAK inhibitor with strong antitumor activity in both hematological and solid tumor xenograft models Cancer Research ·Sanjeeva Reddy, Niranjan Rao, David J. Zammit, Scott K. Thompson, Roger A. Smith, Louis Denis	2017	5
9	ASN003, a highly selective BRAF and PI3K inhibitor: Preclinical and phase 1 clinical data in patients with advanced solid tumors. Journal of Clinical Oncology ·Drew Rasco, Ryan J. Sullivan, Nehal J. Lakhani, Sanjeeva Reddy, Niranjan Rao, Louis Denis, Anthony W. Tolcher, Keith T. Flaherty	2017	2
10	Clinical activity and safety of ASN001, a selective CYP17 lyase inhibitor, administered without prednisone in men with metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology ·Jorge A. García, Robert Dreicer, Allan J. Pantuck, Naomi B. Haas, Ulka N. Vaishampayan, Drew Rasco, Allison Tyler, Niranjan Rao, Yayoi Kurita, Sanjeeva Reddy, Louis Denis, Anthony W. Tolcher	2017	1
11	Abstract 158: ASN003, a highly selective inhibitor of B-Raf and PI3 kinases, shows strong antitumor activity in B-Raf inhibitor resistant patient-derived xenograft models Cancer Research ·Scott K. Thompson, Roger A. Smith, Niranjan Rao, Michael J. Wick, Sanjeeva Reddy	2017	1
12	Abstract B100: ASN003, a unique B-RAF inhibitor with additional selective activity against PI3K and mTOR kinases, shows strong antitumor activity in multiple xenograft models Molecular Cancer Therapeutics ·Scott K. Thompson, Mahaboobi Jaleel, N. H. Whitlock, Murali Ramachandra, Huiying Guo, Dasmi Putra, Vaibhav Sihorkar, Roger A. Smith, Niranjan Rao, 왕연중, Sanjeeva Reddy	2015	3
13	Abstract C134: EN3356, a novel CYP17A inhibitor for the treatment of castration resistant prostate cancer. Molecular Cancer Therapeutics ·Nicholas J. Laping, Sivanandhan Dhanalakshmi, Fatimah Zuhaira Mohamed Yusoff Fauzii, Marta Carlini, José d' Encarnação, J. Kijeński, Ramesh Mullangi, Niranjan Rao, Aranapakam M. Venkatesan, Sanjeeva Reddy, Sandeep Gupta, Roger A. Smith	2013	1
14	A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response Blood ·Keith W. Pratz, Jörge E. Cortes, Gail J. Roboz, Niranjan Rao, Omotayo Arowojolu, Adam Stine, Yukimasa Shiotsu, Sarah Rezapourdamanab, Shiro Akinaga, Donald Small, Judith E. Karp, Mark J. Levis	2008	148
15	A Phase I Dose Escalation Study of KW-2449, An Oral Multi-Kinase Inhibitor against FLT3, Abl, FGFR1 and Aurora in Patients with Relapsed/Refractory AML, ALL and MDS or Resistant/Intolerant CML Blood ·Jörge E. Cortes, Gail J. Roboz, Hagop M. Kantarjian, Eric J. Feldman, Judith E. Karp, Keith W. Pratz, Niranjan Rao, Shiro Akinaga, Mark J. Levis	2008	28
16	The Clinical Pharmacokinetics of Escitalopram Clinical Pharmacokinetics ·Niranjan Rao	2007	182
17	A Phase I Dose Escalation Study of KW-2449, an Oral Multi-Kinase Inhibitor Against FLT3, Abl, FGFR1 and Aurora in Patients with Relapsed/Refractory AML, Treatment Resistant/Intolerant CML, ALL and MDS. Blood ·Jörge E. Cortes, Gail J. Roboz, Hagop M. Kantarjian, Eric J. Feldman, Yan Xiaoxin, Laura Martínez-Caro, Ditte Clausen, Niranjan Rao, Shiro Akinaga, Mark J. Levis	2007	10
18	Investigation of the pharmacokinetic and pharmacodynamic interactions between memantine and glyburide/metformin in healthy young subjects: A single-center, multiple-dose, open-label study Clinical Therapeutics ·Niranjan Rao, Thomas T. Chou, Daniel Ventura, Wattanaporn Abramowitz	2005	24
19	The Pharmacokinetics of Escitalopram After Oral and Intravenous Administration of Single and Multiple Doses to Healthy Subjects The Journal of Clinical Pharmacology ·Birgitte Søgaard, H. Mengel, Niranjan Rao, Frank Larsen	2005	112
20	Lack of Pharmacokinetic or Pharmacodynamic Interaction Between Memantine and Donepezil Annals of Pharmacotherapy ·Antonia Periclou, Daniel Ventura, Dedek Melda Imalia, Niranjan Rao, Wattanaporn Abramowitz	2004	66

About Niranjan Rao

Niranjan Rao is a scholar working on Immunology and Allergy, Genetics, Dermatology, Biological Psychiatry and Hematology, having authored 26 papers that have together received 861 indexed citations. Recurring topics across this work include Melanoma and MAPK Pathways (5 papers), Dermatology and Skin Diseases (4 papers), Chronic Myeloid Leukemia Treatments (4 papers), Monoclonal and Polyclonal Antibodies Research (4 papers), Acute Myeloid Leukemia Research (3 papers), Synthesis and biological activity (3 papers), Chronic Lymphocytic Leukemia Research (3 papers) and Allergic Rhinitis and Sensitization (3 papers). The work is most often cited by research in Dermatology (203 citations), Immunology and Allergy (139 citations), Hematology (163 citations), Biological Psychiatry (36 citations) and Pharmacology (168 citations). Niranjan Rao has collaborated with scholars based in United States, India and Canada. Frequent co-authors include H. Mengel, Birgitte Søgaard, Frank Larsen, Daniel Ventura, Wattanaporn Abramowitz, David J. Zammit, Gail J. Roboz, Mark J. Levis, Shiro Akinaga and Jörge E. Cortes. Their work appears in journals such as Journal of Clinical Oncology, Molecular Cancer Therapeutics, Blood, Cancer Research and Journal of the American Academy of Dermatology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact